Which peptide loses the most weight?

Retatrutide showed the largest mean body-weight reduction in trials at -24.2% over 48 weeks (Jastreboff et al, Phase 2, NEJM 2023). Tirzepatide is the largest FDA-approved effect at -22.5% over 72 weeks (Jastreboff et al, Phase 3 SURMOUNT-1, NEJM 2022). Semaglutide (Ozempic / Wegovy) is -14.9% (Wilding et al, Phase 3 STEP-1, NEJM 2021). These are separate trials with different cohorts and different durations, so the comparison is a directional observation, not a controlled head-to-head finding.

Are GLP-1 peptides the only option for fat loss?

No. Tesamorelin (GHRH analog) is FDA-approved (2010) and targets visceral adipose tissue specifically, not total body weight. MOTS-c (mitochondrial peptide) and SLU-PP-332 (ERR agonist exercise mimetic) operate via different metabolic pathways. GLP-1 agonists (Reta, Tirz, Sema) currently produce the largest measured fat-loss effects, but they are not the only peptides studied for body-composition outcomes.

Can I stack Retatrutide with Tirzepatide?

No. Both are GLP-1 agonists with overlapping mechanism. Stacking them is redundant and adds GI side-effect burden without additional fat-loss benefit. Pick one, titrate slowly. If you want a multi-peptide stack, combine a GLP-1 (one of Reta or Tirz) with a different mechanism: Tesamorelin (visceral fat) or MOTS-c (insulin sensitivity).

Does Peptara sell Ozempic or Wegovy?

No. Peptara does NOT sell semaglutide in any form. Peptara is a research-peptide supplier. Brand pens (Ozempic, Wegovy, Mounjaro, Zepbound) are FDA-approved finished pharmaceuticals available only via prescription. Anyone selling brand pens online is selling gray-market product with no chain-of-custody guarantee. Peptara stocks Retatrutide, Tirzepatide, Tesamorelin, MOTS-c, and SLU-PP-332 as research vials.

What is the difference between visceral and subcutaneous fat loss?

Subcutaneous fat is the layer under the skin (what you can pinch). Visceral fat (VAT) is the deep abdominal fat surrounding internal organs; it is metabolically distinct and more strongly tied to insulin resistance, cardiovascular risk, and type 2 diabetes. GLP-1 agonists (Reta, Tirz, Sema) reduce both compartments via total body weight loss. Tesamorelin specifically targets VAT (-15% in Phase 3) without comparable subcutaneous effect.

Are there fat-loss peptides without GLP-1 side effects (nausea, etc.)?

Yes. Tesamorelin (GH axis), MOTS-c (mitochondrial), and SLU-PP-332 (ERR agonist) operate outside the GLP-1 pathway and do not share the appetite-mediated GI profile. Trade-off: smaller effect on total body weight than the GLP-1 class, and less clinical validation. Tesamorelin is the most validated non-GLP-1 option for fat-targeting (FDA-approved 2010 for VAT reduction).

How long until I see results?

GLP-1 class (Reta, Tirz, Sema): 4 to 8 weeks at starting dose for early appetite and scale changes; major body weight reduction typically takes 24+ weeks of titration to peak dose. Tesamorelin: 12 to 26 weeks for visceral fat measurable reduction (imaging-based endpoint). MOTS-c: 4 to 12 weeks for insulin sensitivity / metabolic marker changes. Individual response varies substantially.

Is FDA approval important if the molecule is the same?

FDA approval certifies the finished pharmaceutical (manufacturing, fill-finish, sterility, labeling, dose accuracy), not the molecule itself. The molecule is identical whether it is Mounjaro brand pen or a research vial of tirzepatide. What differs is the regulatory pathway (Rx-only finished product vs research compound), the supply chain (pharmacy chain-of-custody vs research supplier), the packaging (pre-titrated pen vs lyo vial requiring reconstitution), and the price (FDA-approved finished product carries the FDA-approval premium). Choose based on regulatory comfort, format preference, and budget.

Topic hub: fat loss

Best Peptides for Fat Loss: Ranked by Trial Effect Size

Six compounds ranked by trial body-weight reduction. From -24.2% Phase 2 (retatrutide) to preclinical-only (SLU-PP-332). Vendor-neutral. Includes FDA status, monthly cost, and a goal-based decision tree.

Verdict in 5 lines

Biggest trial effect: Retatrutide -24.2% body weight at 12mg/wk (Phase 2, NEJM 2023).
Biggest FDA-approved effect: Tirzepatide -22.5% at 15mg/wk (Phase 3 SURMOUNT-1, NEJM 2022).
Longest safety record: Semaglutide -14.9% at 2.4mg/wk (Phase 3 STEP-1, NEJM 2021). Peptara does NOT sell semaglutide.
Visceral-fat-specific: Tesamorelin -15% VAT (not total body weight) at 2mg/day (Phase 3, NEJM 2007).
Different trials, different cohorts, different durations. Effect-size comparison across trials is a directional observation, not a controlled head-to-head finding.

Ranked by trial effect size

Sourced from peer-reviewed clinical trials (NEJM 2007, 2021, 2022, 2023). Effect-size comparisons across separate studies are directional, not controlled head-to-head.

Rank	Peptide	Peak Trial Effect	Phase / Source	FDA Status (obesity)	Peptara Cost
1	Retatrutide	-24.2% body weight	Phase 2 Jastreboff et al, NEJM 2023	Research compound. Phase 3 ongoing.	$75 to $452 first-time
2	Tirzepatide	-22.5% body weight	Phase 3 Jastreboff et al, NEJM 2022 (SURMOUNT-1)	Zepbound FDA-approved Nov 2023 (brand pen). Peptara sells research vial.	$85 to $510 first-time
3	Semaglutide (Ozempic / Wegovy)	-14.9% body weight	Phase 3 Wilding et al, NEJM 2021 (STEP-1)	Wegovy FDA-approved Jun 2021	NOT sold by Peptara. US retail $968 to $1,349/mo
4	Tesamorelin	-15% visceral adipose tissue (VAT)	Phase 3 Falutz et al, NEJM 2007	FDA-approved 2010 (HIV-associated lipodystrophy). Off-label / research for general VAT.	about $440/mo first-time (1mg/day)
5	MOTS-c	Metabolism + insulin sensitivity (no Phase 3 obesity trial)	Preclinical + small human Lee et al, Cell Metab 2015	Research compound	$85 to $170/mo first-time (5 to 10mg/wk)
6	SLU-PP-332	Exercise mimetic (no human obesity trials)	Preclinical (mouse only) Billon et al, J Pharmacol Exp Ther 2023	Research compound	$157/vial, biohacker dosing varies

Read this before quoting the ranking

Different trials, different cohorts, different durations, different placebo response calibration. These effect sizes are a directional comparison across separate studies, not a controlled head-to-head finding. Retatrutide Phase 3 results from the TRIUMPH program may report different numbers than Phase 2. SURMOUNT-1 ran 72 weeks; STEP-1 ran 68 weeks. Tesamorelin measured visceral fat (VAT) not total body weight, which is a different endpoint.

Decide by goal

Six goal profiles, six recommendations. Pick the card that matches what you actually care about.

Goal A

Biggest weight loss number

Triple-agonist GLP-1 + GIP + glucagon. Largest trial effect (-24.2% Phase 2). Trade-off: Phase 3 still collecting. Research compound, not FDA-approved.

Pick: Retatrutide

Retatrutide product →vs Tirzepatide →vs Ozempic →

Goal B

FDA-approved, longest safety record

Single-agonist GLP-1. Years of cardiovascular outcome data (SUSTAIN, SELECT). Trade-off: smallest trial effect of the GLP-1 class (-14.9% STEP-1). US retail $968 to $1,349/mo cash. Peptara does NOT sell semaglutide.

Pick: Semaglutide (Ozempic / Wegovy)

Reta vs Ozempic →Tirz vs Ozempic →

Goal C

FDA-approved, biggest trial effect

Dual-agonist GLP-1 + GIP. -22.5% Phase 3 SURMOUNT-1. FDA-approved as Mounjaro (T2D, 2022) and Zepbound (obesity, 2023). Peptara sells research vial at 10 to 15x lower starting-dose cost.

Pick: Tirzepatide

Tirzepatide product →vs Ozempic →

Goal D

Belly / visceral fat specifically

GHRH analog. Stimulates pulsatile GH leading to IGF-1 leading to preferential VAT reduction. Different endpoint: -15% visceral adipose tissue (NOT total body weight). FDA-approved 2010 (Egrifta) for HIV-associated lipodystrophy. Used off-label or research for visceral fat in non-HIV populations.

Pick: Tesamorelin

Available via Peptara, no dedicated product page yet. Contact WhatsApp.

Goal E

Metabolism + insulin sensitivity, no GLP-1 GI

Mitochondrial-derived peptide. Boosts cellular energy and insulin sensitivity. Fat-loss-adjacent, not primary fat-loss. No Phase 3 obesity trial. Preclinical plus small human studies on aging and metabolism.

Pick: MOTS-c

Available via Peptara, no dedicated product page yet. Contact WhatsApp.

Goal F

Endurance / fat oxidation, not appetite suppression

ERR receptor agonist. Exercise-in-a-vial mechanism. Preclinical mouse data only. NO human obesity trials. For research / biohacker use, not validated for fat loss in humans.

Pick: SLU-PP-332

Available via Peptara, no dedicated product page yet. Contact WhatsApp.

Mechanism groups

Three biological pathways, six compounds.

GLP-1 class (appetite + metabolic)

Retatrutide (triple agonist), Tirzepatide (dual), Semaglutide (single). Activate the gut-brain satiety axis plus insulin / glucagon regulation. Mechanism of action shared; receptor count differs.

GH axis (visceral fat-specific)

Tesamorelin (GHRH analog). Stimulates endogenous GH release leading to IGF-1 leading to preferential visceral adipose tissue reduction. Different endpoint than GLP-1s.

Mitochondrial / exercise mimetic

MOTS-c (mitochondrial peptide), SLU-PP-332 (ERR agonist). Boost cellular energy and fat oxidation. Less validated for fat loss; closer to metabolic optimization. Emerging class.

Cost breakdown

Peptara monthly cost ranges with first-time discount applied. Cost formula: vial price times 4.33 weeks per month, divided by weeks per vial.

Peptide	Vial	First-time / Retail	Common Dose	Monthly first-time	Monthly retail
Retatrutide	20mg	$174 / $205	2mg to 12mg/wk titration	$75 to $452	$89 to $533
Tirzepatide	20mg	$157 / $185	2.5mg to 15mg/wk titration	$85 to $510	$100 to $601
Tesamorelin	10mg	$145 / $170	1mg/day common research	about $440	about $515
MOTS-c	40mg	$157 / $185	5 to 10mg/wk	about $85 to $170	about $100 to $200
SLU-PP-332	5mg	$157 / $185	Research-only, varies	Varies	Varies

External US retail reference (not Peptara pricing)

Ozempic about $968/mo, Wegovy about $1,349/mo (Novo Nordisk cash list). Compounded semaglutide about $200 to $400/mo (FDA-restricted after October 2024 shortage resolution). Peptara does NOT sell semaglutide.

Monthly cost calculation: vial price times 4.33 weeks/month divided by weeks per vial. Reta and Tirz use 20mg per vial reconstituted in 2mL bac water for 200 units per vial at 0.1mg per unit. Doses always in units, never mL. See the reconstitution guide for full math.

Stacking framework

What to combine, what to avoid, how to sequence.

Smart stacks

Retatrutide OR Tirzepatide plus Tesamorelin (total body + visceral)
Retatrutide OR Tirzepatide plus MOTS-c (appetite + insulin sensitivity)
GLP-1 plus CJC-1295 / Ipamorelin (lean mass retention during fat loss). See the quiz.

Avoid

Retatrutide + Tirzepatide (redundant GLP-1 mechanism, additive GI)
Tirzepatide + Semaglutide (redundant GLP-1, GI compounding)
Retatrutide + Semaglutide (redundant; sema is FDA-approved Rx, do not mix with research compound without physician guidance)

Sequencing

Start with ONE compound, titrate slowly (monthly steps), establish baseline
Add a stack compound only after 8 to 12 weeks on the primary
If discontinuing a GLP-1, taper rather than abrupt stop (appetite + glucose homeostasis adjustment)

FDA status and regulatory landscape

Two FDA-approved as brand pens (Tirz, Sema). One FDA-approved for a specific non-obesity indication (Tesamorelin, HIV-associated lipodystrophy). Three research compounds.

Peptide	Status	FDA Approval Date	Available Form
Retatrutide	Research compound	Phase 3 ongoing (TRIUMPH program)	Research vial only
Tirzepatide	FDA-approved (brand pens)	Mounjaro May 2022 (T2D), Zepbound Nov 2023 (obesity)	Brand pre-filled pen via Rx; research vial via Peptara
Semaglutide (Ozempic / Wegovy)	FDA-approved (brand pens)	Ozempic Dec 2017, Wegovy Jun 2021	Brand pre-filled pen via Rx ONLY. Peptara does not sell.
Tesamorelin	FDA-approved (Egrifta)	Nov 2010	FDA-approved for HIV-associated lipodystrophy. Off-label / research for general VAT reduction.
MOTS-c	Research compound	N/A	Research vial only
SLU-PP-332	Research compound	N/A	Research vial only (preclinical data; not for clinical use)

Side effects by mechanism group

Three profiles to know.

GLP-1 class (Reta + Tirz + Sema)

Nausea, diarrhea, constipation, vomiting. Most pronounced during titration and at higher doses; usually resolves over 4 to 8 weeks per dose step. GLP-1 class carries thyroid C-cell black-box warning (rodent signal; no confirmed human cases). Trial-reported nausea rates: Reta about 30% at 12mg, Tirz about 30% at 15mg, Sema about 20% at 2.4mg.

GH-axis (Tesamorelin)

Injection-site reactions, joint pain, fluid retention. May elevate IGF-1 (monitor lab values for longer protocols). Avoid in active malignancy and diabetic retinopathy.

Mitochondrial + exercise mimetic (MOTS-c, SLU-PP-332)

Limited human data. MOTS-c well-tolerated in small studies. SLU-PP-332 long-term human safety not established (preclinical only). Standard research-compound caveats apply.

Timeline expectations

How long until you see effects.

Peptide	Dose Schedule	Time to Visible Effect
Retatrutide	Weekly injection	4 to 8 weeks at starting dose; major weight change at 24+ weeks
Tirzepatide	Weekly injection	4 to 8 weeks at starting dose; major weight change at 24+ weeks
Semaglutide	Weekly injection (brand pen)	4 to 8 weeks at starting dose; major weight change at 24+ weeks
Tesamorelin	Daily injection	12 to 26 weeks for visceral fat measurable reduction
MOTS-c	2x weekly	4 to 12 weeks for insulin sensitivity and metabolic markers
SLU-PP-332	Research-protocol-dependent	No human obesity timeline established

Frequently asked questions

Next steps

Retatrutide product page

Triple-agonist research vial. $174 first-time / $205 retail. 20mg/vial.

View product

Tirzepatide product page

Dual-agonist research vial (same molecule as Mounjaro / Zepbound). $157 / $185. 20mg/vial.

View product

How to reconstitute your vial

4-step method plus units-not-mL calculator. Required reading before any research-vial protocol.

Open guide

Full /vs/* cluster

Reta vs Tirz Reta vs Ozempic Tirz vs Ozempic BPC vs TB-500

FAQ →About Peptara →Find your protocol quiz →

Not sure which peptide fits your goal

Not sure which peptide fits your goal? Message the Peptara team on WhatsApp.

We answer protocol questions, not medical questions. For Tesamorelin, MOTS-c, and SLU-PP-332 (no dedicated product page yet), WhatsApp is the order channel.

Chat on WhatsApp Browse all 15 peptides →